**Background of ATP5G Antibodies**
ATP5G antibodies target subunits of the mitochondrial ATP synthase complex, specifically the *ATP5G1*, *ATP5G2*, and *ATP5G3* isoforms (also termed *ATP5F1C*, *ATP5PD*, and *ATP5PE*), which form the c-subunit of the Fo region. This transmembrane domain is critical for proton translocation during ATP synthesis, coupling the proton gradient to ATP production via the F1 catalytic core. Dysregulation of ATP synthase is linked to mitochondrial disorders, cancer, and neurodegenerative diseases.
ATP5G antibodies are essential tools for studying ATP synthase expression, localization, and function. They are widely used in techniques like Western blot, immunohistochemistry (IHC), and immunofluorescence (IF) to assess mitochondrial health, energy metabolism, or disease mechanisms. For example, altered ATP5G levels have been observed in tumors (e.g., upregulated in certain cancers to meet metabolic demands) and in neurodegenerative conditions like Alzheimer’s, where mitochondrial dysfunction occurs.
These antibodies also aid in investigating therapeutic responses, such as drugs targeting oxidative phosphorylation. Specificity is crucial, as isoforms vary in tissue distribution (e.g., ATP5G3 is testis-specific). Researchers must validate antibodies using knockout controls to ensure accurate detection. Overall, ATP5G antibodies provide insights into cellular bioenergetics and disease pathways tied to mitochondrial ATP synthesis.